BIOPLUS ACQUISITION Stock Price, News & Analysis
BIOSW
Company Description
BioPlus Acquisition Corp. (BIOSW) is a company focused on effecting mergers, capital stock exchanges, asset acquisitions, and reorganizations within the healthcare industry across the U.S., EU, Israel, and Australasia. It recently announced the termination of a business combination agreement and plans to liquidate, intending to return funds to shareholders. BIOSW expects to redeem all public shares for an estimated price per share and dissolve in accordance with its Charter. The company sponsor has waived redemption rights for certain shares, and there will be no liquidating distributions for warrants.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for BIOPLUS ACQUISITION.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is BioPlus Acquisition Corp. focused on?
BIOSW is focused on effecting mergers, capital stock exchanges, asset acquisitions, and reorganizations within the healthcare industry across the U.S., EU, Israel, and Australasia.
What recent announcement did BioPlus Acquisition Corp. make?
BIOSW announced the termination of a business combination agreement and its intention to liquidate, returning funds to shareholders.
What is the estimated redemption price per share for public shares?
BIOSW expects to redeem all public shares for an estimated price of approximately $10.79 per share.
What rights does the company sponsor waive with respect to certain shares?
The company sponsor has agreed to waive redemption rights for outstanding Class B ordinary shares issued prior to the initial public offering and Class A ordinary shares included in units issued in a private placement concurrent with the IPO.
Will there be liquidating distributions for warrants?
There will be no redemption rights or liquidating distributions with respect to the company's warrants, which will expire worthless.